1. Generics Bulletin

Lannett Looks To Transform Company With Five Pipeline Assets

As Company Reports Another Low Financial Quarter

 
• By Akriti Seth

With five “large, durable assets” in its pipeline, Lannett is confident that post approval these products have the potential to transform the company. This includes the generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) recently added to Lannett’s respiratory generics portfolio. 

strategy
Lannett expects five approvals by 2025 • Source: Alamy

Capitalizing on five lucrative pipeline assets, including the US generic version of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) in partnership with Respirent, could be transformational for Lannett Company, Inc., the US firm has underlined. The company recently signed a 10-year agreement with the Chinese respiratory developer for generic Spiriva Handihaler. (see sidebar) 

Lannett CEO Tim Crew said, “With the recently signed agreement to be the exclusive US distributor of generic Spiriva Handihaler, we now have disclosed at

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.